BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35646640)

  • 1. The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation.
    Cui J; Li L; Yuan S
    Front Oncol; 2022; 12():863715. PubMed ID: 35646640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.
    Spagnuolo A; Muto M; Monaco F; Colantuoni G; Gridelli C
    Transl Lung Cancer Res; 2019 Dec; 8(6):1134-1151. PubMed ID: 32010591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
    Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
    BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q; Liu J; Li D; Xu C
    World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
    Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma
    Wang X; Liu Y; Meng Z; Wu Y; Wang S; Jin G; Qin Y; Wang F; Wang J; Zhou H; Su X; Fu X; Wang X; Shi X; Wen Z; Jia X; Qin Q; Gao Y; Guo W; Lu S
    Ann Transl Med; 2021 Apr; 9(8):635. PubMed ID: 33987333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.
    Singh R; Lehrer EJ; Ko S; Peterson J; Lou Y; Porter AB; Kotecha R; Brown PD; Zaorsky NG; Trifiletti DM
    Radiother Oncol; 2020 Mar; 144():165-179. PubMed ID: 31812932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
    Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
    J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
    Wang W; Sun X; Hui Z
    Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.
    Saida Y; Watanabe S; Abe T; Shoji S; Nozaki K; Ichikawa K; Kondo R; Koyama K; Miura S; Tanaka H; Okajima M; Terada M; Ishida T; Tsukada H; Makino M; Iwashima A; Sato K; Matsumoto N; Yoshizawa H; Kikuchi T
    Thorac Cancer; 2019 Nov; 10(11):2106-2116. PubMed ID: 31507098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
    Jia F; Cheng X; Zeng H; Miao J; Hou M
    J BUON; 2019; 24(2):578-584. PubMed ID: 31128009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.